Mycenax Biotech (永昕) announced at its investor conference on the 29th that it is deepening its Japanese strategic layout. Chairperson Chen Pei-chun revealed a joint venture with three major Japanese firms—Alfresa Holdings, Kidswell Bio, and Chiome Bioscience—to establish Alfenax Biologics Corporation. The venture involves an investment exceeding NT$3 billion to build a production base in Japan.
Read more
